Overview

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study is designed in two parts. Part 1 will assess the safety and tolerability of different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood pressure with protein in urine). Part 2 will assess whether an optimal dose of RLX030 can prolong pregnancy in women with pre-eclampsia.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals